Background: Glioma grading between intermediate grades (Grade II vs. III and Grade III vs. IV) as well as multiclass grades (Grade II vs. III vs. IV) is challenging and needs to be addressed.

Purpose: To develop an artificial intelligence-based methodology for glioma grading using T perfusion parameters and volume of tumor components, and validate the efficacy of the methodology by grading on a cohort of glioma patients.

Study Type: Retrospective.

Population: The development set consisted of 53 glioma patients and validation consisted of 13 glioma patients.

Field Strength/sequence: Conventional MRI images (2D T -W, dual PD-T -W, and 3D FLAIR) and 3D T perfusion MRI data obtained at 3 T.

Assessment: Enhancing and nonenhancing components of glioma were segmented out and combined to form the region of interest (ROI) for glioma grading. Prominent vessels were removed from the selected ROI. Different T perfusion parameters from the ROI were combined with volume of tumor components to form the feature set for glioma grading. Optimization was carried out for selection of the statistic of the T perfusion parameters and the features to be used for glioma grading using sequential feature selection and random forest-based feature selection method. An optimized support vector machine (SVM) classifier was used for glioma grading.

Statistical Tests: Mean ± SD, analysis of variance (ANOVA) followed by the Tukey-Kramer test, ROC analysis.

Results: Classification error for Grade II vs. III was 3.7%, for Grade III vs. IV was 5.26%, and for Grade II vs. III vs. IV was 9.43% using the proposed methodology. The mean of the values above the 90 percentile value of T perfusion parameters provided a maximum area under the curve (AUC) for intermediate grade differentiation. Random forest obtained optimal feature set provided better grading results than other methods using the SVM classifier.

Data Conclusion: It was feasible to achieve low classification error for intermediate as well as multiclass glioma grading using an SVM classifier based on optimized features obtained from T perfusion MRI and volumes of tumor components.

Level Of Evidence: 4 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2019;50:1295-1306.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.26704DOI Listing

Publication Analysis

Top Keywords

glioma grading
28
grade iii
24
perfusion parameters
16
glioma
12
perfusion mri
12
tumor components
12
based optimized
8
optimized features
8
features perfusion
8
mri volumes
8

Similar Publications

Malignant gliomas are heterogeneous tumors, mostly incurable, arising in the central nervous system (CNS) driven by genetic, epigenetic, and metabolic aberrations. Mutations in isocitrate dehydrogenase (IDH1/2) enzymes are predominantly found in low-grade gliomas and secondary high-grade gliomas, with IDH1 mutations being more prevalent. Mutant-IDH1/2 confers a gain-of-function activity that favors the conversion of a-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG), resulting in an aberrant hypermethylation phenotype.

View Article and Find Full Text PDF

Objective: The objective was to comprehensively investigate the clinical, molecular, and imaging characteristics and outcomes of H3 K27-altered diffuse midline glioma (DMG) in adults.

Methods: Retrospective chart and imaging reviews were performed in 111 adult patients with H3 K27-altered DMG from two tertiary institutions. Clinical, molecular, imaging, and survival characteristics were analyzed.

View Article and Find Full Text PDF

Rationale: Ependymomas are commonly prevalent intramedullary neoplasms in adults, with hardly any cases of exophytic extramedullary ependymoma being reported. Meningiomas, on the contrary, are one of the most common intradural extramedullary (IDEM) tumors. However, the occurrence of both IDEM tumors simultaneously is extremely rare.

View Article and Find Full Text PDF

Objective: Gliomas are a general designation for neuroepithelial tumors derived from the glial cells of the central nervous system. According to the histopathological and immunohistochemical features, the World Health Organization classifies gliomas into four grades. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor that has been approved for the treatment of glioblastoma multiforme (GBM) as a second-line therapy.

View Article and Find Full Text PDF

Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.

Neuro Oncol

January 2025

Childhood Cancer & Cell Death team (C3 team), Consortium South-ROCK, LabEx DEVweCAN, Institut Convergence Plascan, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, 69008 Lyon, France.

Background: Brain tumors are the deadliest solid tumors in children and adolescents. Most of these tumors are glial in origin and exhibit strong heterogeneity, hampering the development of effective therapeutic strategies. In the past decades, patient-derived tumor organoids (PDT-O) have emerged as powerful tools for modeling tumoral cell diversity and dynamics, and they could then help defining new therapeutic options for pediatric brain tumors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!